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a b s t r a c t
This paper describes the synthesis and characterization of four new ruthenium complexes containing 1,4
bis(diphenylphosphino)butane (dppb), 2-pyridinecarboxylic acid anion (pic) and the diimines [(2,20-
bipyridine (bipy), 4,40-dimethyl-2,20-bipyridine (Me-bipy), 4,40-dichloro-2,20-bipyridine (Cl-bipy) and
1,10-phenanthroline (phen) as ligands, with formulae [Ru(pic)(dppb)(bipy)]PF6 (SCAR01), [Ru(pic)(dppb)
(Me-bipy)]PF6 (SCAR02), [Ru(pic)(dppb)(Cl-bipy)]PF6 (SCAR03) and [Ru(pic)(dppb)(phen)]PF6 (SCAR04).
Additionally, the in vitro anti-Mycobacterium tuberculosis (MTB) activity, cytotoxicity and activity against
in vitro infection of these complexes and two more complexes, cis-[Ru(pic)(dppe)2]PF6 (SCAR05) and cis-
[RuCl2(dppb)(bipy)] (SCAR06), and their free ligands are described and discussed. All compounds
showed excellent MIC against MTB, low cytotoxicity and a selectivity index higher than 10. Also, all
compounds showed signiﬁcant intracellular inhibition and the compound SCAR05 showed a better
activity than rifampin and SQ109. This is the ﬁrst report of activity against in vitro infection of ruthenium
compounds.
 2011 Elsevier Masson SAS. All rights reserved.
1. Introduction
The tuberculosis (TB) mortality rates decreased globally in 2007,
with 1.3 million HIV-negative TB patients dying in 2007 and
456,000 deaths among individuals infected with both TB and HIV.
However, in 2007 there were an estimated 9.27 million incident
cases of TB, themajority of which occurred in Asia and Africa. This is
an increase from the previous year, when 9.24 million cases were
recorded [1]. In addition, the highly drug-resistant organisms are
virtually untreatable in immunocompetent patients, so when these
organisms enter into contact with highly immunocompromised
HIV-infected populations, the mortality rate within a few weeks of
infection approaches 100% [2]. In the last 40 years, no new drugs
have been developed speciﬁcally against mycobacteria [3] and, only
in the last few years, some promising candidate drugs are being
tested in the preclinical phase [4]. Thus, there is a great need to
develop new therapeutic agents to treat tuberculosis, so as to
reduce the total duration of treatment and to provide more effec-
tive treatment against multidrug resistance (MDR), extensive drug
resistance (XDR) and latent tuberculosis infection [5]. There are
currently two main approaches to developing a new anti-TB drug
[6]. One of them is based on the synthesis of analogues of existing
drugs, with the aim of shortening and improving TB treatment. The
other involves a search for novel structures with which mycobac-
teria have never been challenged before [7]. Adopting this second
approach, our research is focused on the synthesis and character-
ization of new compounds, speciﬁcally new metal complexes.
Medicinal chemistry is taking a growing interest in the devel-
opment of metal complexes for use as drugs or diagnostic agents.
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Owing to their wide spectrum of coordination numbers and
geometries, as well as kinetic properties, metal compounds offer
mechanisms of drug action that cannot be realized by organic
agents [7,8]. Ruthenium compounds have already exhibited
potential anti-tumour activity since the 1970s and 1980s, and, more
recently, the Ru(III) complexes NAMI-A and KP 1019 (FFC14a) have
entered clinical trials. Recent studies have indicated that the anti-
tumour activity of Ru(III) complexes also depends on their reduc-
ibility to Ru(II) species. The in vitro activity of a homologous series
of Ru(III) complexes increased with increasing ease of reduction [8].
In this laboratory, we have studied and reported on the anti-
Mycobacterium tuberculosis (MTB) activity of several new
complexes containing various metals [3,7,9e14]. Speciﬁcally, Ru(II)
complexes have shown excellent activity against in vitroMTB, being
up to 150 times more active than their free ligands 4,6-dimethyl-2-
mercaptopyrimidine; 1,4 bis(diphenylphosphino)butane; 1,2-
bis(diphenylphosphio)ethane, bis(diphenylphosphino) methane,
triphenylphosphine, 2,20-bipyridine, 4,40-dimethyl-2,20-bipyridine,
2-pyridinecarboxylic acid and, interestingly, in these complexes the
activity was higher, when they contained three chelated ligands,
than that of the precursor complexes containing two chelated and
two chloride ligands [9,14].
This paper describes the synthesis and characterization of four
new ruthenium(II) complexes containing 1,4 bis(diphenylphos-
phino)butane (dppb), the 2-pyridinecarboxylic acid anion (pic) and
diimines (bipy, Me-bipy, Cl-bipy and phen) as ligands, with
formulae [Ru(pic)(dppb)(bipy)]PF6 (SCAR01), [Ru(pic)(dppb)(Me-
bipy)]PF6 (SCAR02), [Ru(pic)(dppb)(Cl-bipy)]PF6 (SCAR03) and
[Ru(pic)(dppb)(phen)]PF6 (SCAR04). Additionally, the in vitro anti-
M. tuberculosis (MTB) activity, cytotoxicity and activity against
in vitro infection of these complexes and two more complexes, cis-
[Ru(pic)(dppe)2]PF6 (SCAR05) and cis-[RuCl2(dppb)(bipy)]
(SCAR06) [9,15], and their free ligands are presented and discussed.
2. Results and discussion
2.1. Synthesis of the complexes
The chemical reactivity of the 2-pyridinecarboxylic acid (Hpic)
ligand with complexes such as cis-[RuCl2(dppb)(N-N)] [15] enabled
the synthesis of complexes with the general formula
[Ru(pic)(dppb)(NeN)]PF6 (N-N ¼ bipy, Me-bipy, Cl-bipy or phen),
containing three chelated ligands, under mild conditions, by simple
chloride exchange (see Scheme 1).
2.2. Structural studies
The X-ray structure of SCAR01 was determined and an ORTEP
view showing the atom numbering scheme is shown in Fig. 1.
Selected bond lengths and angles are presented in Table 1. The
crystal structure of the complex consists of separate discrete
molecular units and solvated water molecules (w). Complex
SCAR01 crystallizes in the monoclinic system, space group P21/n,
the Ru center being coordinated by three bidentate ligands in
a distorted octahedral geometry as shown by the angles around the
metal ion, listed in Table 1. One phosphorus atom is disposed trans
to one nitrogen atom of the bipy and the other trans to the oxygen
of the pic ligand.
The RueP bond lengths of 2.3256(18) and 2.350(2) Å are within
the normal range found for Ru(II) tertiary phosphine complexes
[15e19]. The PeRueP angle in the seven-member ring of dppb is
99.36(7), comparable with the values previously observed for the
precursor SCAR05 [15]. The average Ru-N (bipy) distance of 2.099 Å
in complex SCAR01 is also similar to that observed in SCAR05
(2.09 Å) [15]. The Ru-N(3) and RueO(1) distances of the pic ligand,
of 2.116(5) and 2.132(5)Å, respectively, are similar to those observed
in other Ru(II) complexes containing this ligand [20,21]. The pic
ligand dimensions in complex SCAR01 (C(22)eO(1) ¼ 1.274(9) Å,
C(22)-O(2) ¼ 1.219(9) Å) are consistent with deprotonation and
coordination of the heterocycle to the Ru center [20,21]. The ﬁve-
membered ring formed by the O-,N- chelating heterocyclic picoli-
nate is inherently strained [20,21]. This is corroborated in SCAR01
by the small O(1)eRueN(3) angle of 77.9(2).
2.3. Characterization of the compounds
The 31P{1H} NMR spectra of complexes SCAR01-4 in CH2Cl2/D2O
in a capillary presented typical AB spin systems exhibiting chemical
shifts close to 39.0 (d) and 37.3 (d), with 2JP-P ¼ 33.5 Hz, indicating
the magnetic nonequivalence of the two phosphorus atoms
N
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OH
O
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Scheme 1. Synthesis of the ruthenium(II) compounds containing the pic ligand.
Fig. 1. ORTEP view of the cation complex [Ru(pic)(dppb)(bipy)]PF6$2H2O (SCAR01)
showing the labels and 50% probability ellipsoids of the atoms. The solvent molecules
were omitted.
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(complete data in Table 2). Precursor complexes of general formula
cis-[RuCl2(dppb)(N-N)] show a pair of doublets at 43.0 and
32.0 ppm, with 2JP-P ¼ 32.0 Hz, in their 31P{1H} spectra [15,22]. In
the precursors, the high-ﬁeld doublet corresponds to the P trans N,
as previously described [15]. These assignments are based on an
empirical linear correlation established between the crystallo-
graphically determined RueP distances in a series of Ru-dppb
complexes and the corresponding 31P chemical shifts observed in
solution, in which the chemical shifts become more high-ﬁeld with
increasing RueP bond length [15,16,19]. In light of this information,
we suggest that in the new complexes the high-ﬁeld doublet
belongs to the P trans to nitrogen from bipy (N-N), because the Ru-
P1 distance of 2.347(3) Å (trans N-N) is longer than that observed
for the Ru-P2 trans O of the pic ligand (2.324(2) Å) (see Table 1).
The mass spectra (ESI-MS) of complexes SCAR01-4, delivered in
a CH2Cl2 solution, showed the parent molecular ions at m/z values
[M  PF6]þ consistent with the assigned formulation (see experi-
mental data). No fragmentation was observed under the experi-
mental conditions described.
The IR spectra of the new complexes also conﬁrmed the pres-
ence of the pic ligand coordinated to the Ru(II) center. Bands cor-
responding to the nas(COO) and ns(COO) vibrational modes
appeared close to 1660 and 1334 cm1, respectively, for all
complexes. The band attributable to n(OH), which appeared at
3200-3100 cm1 in the free ligand spectrum, was absent in those of
complexes SCAR01-4, indicating that the pic ligand is coordinated
in the deprotonated form [23]. The electronic spectra of SCAR01-4
complexes showed four absorptions in the UV region (two bands
and two shoulders), assigned as intra-ligand transitions by means
of comparison with the free ligands (dppb, NeN and pic). In the
visible region, one band and a shoulder were observed, respectively
close to 420 and 490 nm. These absorptions can be attributed to
metal-to-ligand charge transfer transitions, probably involving
both diimine (NeN) and pic ligands. The electrochemical behavior
of these new complexes in cyclic voltammetric experiments was
similar to that observed for their precursors [15,29]. A quasi-
reversible one-electron RuII/RuIII redox process was observed for
each complex. As expected, the E1/2 values found for the new
complexes were considerably more anodic than those observed for
the respective precursors, by approximately 0.60 V (Table 2), indi-
cating that the Ru center was more stable in the new derivatives
than in their precursors. This stabilization is assumed to be due to
the replacement of two monoanionic donor chlorides by a single
monocharged chelating pic unit, resulting in positively-charged
product complexes [24]. Among the four new complexes, the E1/2
values clearly correlate with the diimine pKa values, such that the
complex containing the most acidic ligand (Cl-bipy) showed the
most stable ruthenium center (highest E1/2).
2.4. Anti-M. tuberculosis activity assay
The in vitro anti-MTB activities of the free ligands and the
phosphine-diimine-picolinate ruthenium complexes were tested
against MTB H37Rv ATCC 27294 and the MICs are reported in
Table 3. The MICs of complexes SCAR01-05 are comparable to or
better than those of some “second” and “ﬁrst” line drugs used in
current therapy [6,25,26]. SQ 109, an antitubercular compound
derived from ethambutol, with MIC of 1.56 mM [27], and TMC 207,
a diarylquinoline with MIC of 0.81 mM [28], both of which are new
promising drug candidates, presently in the human clinical trial
phase, are examples of in vitro activity comparable to the ruthe-
nium complexes presented here. Even though the complex SCAR06
showed theworst inhibitory result among the tested compounds, it
had activity comparable to or better than the “second” line drugs
[25]. Comparing the complexes SCAR01 and SCAR06, we observe
that SCAR01 is 5.5 times more active than SCAR06, probably due to
the absence of the Hpic ligand in the latter. The ligands dppe and
phen are the only ones that have good MICs (15.70 and 11.80 mM
respectively). However, these values are respectively 71 and 16
times higher than those of their complexes.
2.5. In vitro cytotoxicity
The cytotoxicity results (Table 3), expressed as the IC50 for the
J774A.1 cell line, show that all of the tested ruthenium complexes
exhibited low cytotoxicity (IC50 ranging from 3.4 to 104 mM). The
free ligands are also not very cytotoxic (IC50 ranging from 50 to
2538 mM). The selectivity index (SI) of each compound was deter-
mined as the ratio of IC50 to MIC (Table 3). According to Orme et al.
[29], candidates for new drugs must have an index equal to or
higher than 10, together with MIC lower than 6.25 mg/mL (or the
molar equivalent) and a low cytotoxicity. SI is used to estimate the
therapeutic window of a drug and to identify drug candidates for
further studies. Thus, all the ruthenium complexes studied here,
with SI ranging from 15.20 to 40.10, are very promising new anti-
tuberculosis drug candidates, and therefore they were all tested
in the in vitro infection model [29].
2.6. In vitro infection model
The in vitro intracellular activities of the phosphine-diimine-
picolinate ruthenium complexes were tested against MTB Erd-
mann (ATCC 35801) containing the Luciferase Plasmid and the
inhibitory values are reported in Table 4. The compounds were
tested in macrophages at those concentrations: at their MICs and 4
times higher and lower. All complexes presented signiﬁcant intra-
cellular activity at various concentrations. The complexes SCAR02
and SCAR05 were the most active because they showed the best
activity at lower concentrations (0.13 mM ¼ 70.50% inhibition and
0.06 mM ¼ 47.60% inhibition, respectively). These complexes also
exhibited the best activity at concentrations equal to and higher
than the MIC. The comparison between the intracellular activity of
compound SCAR05 and rifampin (Table 4) showed a higher activity
in the new compound. Additionally, the intracellular activities of
compounds SCAR01-05 are better than those of 26 synthesized
compounds from a combinatorial library of 1,2-ethylenediamines,
and comparable to SQ 109 (4.72 mM ¼ 99% intracellular inhibition),
Table 1
Selected bond lengths (Å) and angles () for complex [Ru(pic)(dppb)(bipy)]PF6$2H2O
with standard deviations in parentheses.
RueN(1) 2.088(6) N(1)eRueN(2) 79.6(3) N(3)eRue0(1) 78.3(2)
RueN(2) 2.094(7) N(1)eRueN(3) 167.9(3) O(1)eRueP(2) 172.30(17)
RueN(3) 2.112(6) N(2)eRueN(3) 93.0(2) O(1)eRueP(1) 87.96(18)
RueO(1) 2.122(5) N(1)eRueO(1) 91.0(2) N(1)eRueP(1) 96.0(2)
RueP(1) 2.347(3) N(2)eRueO(1) 79.9(2) N(2)eRueP(1) 166.99(17)
RueP(2) 2.324(2) N(3)eRueO(1) 78.3(2) N(3)eRueP(1) 89.1(2)
O(1)eC(22) 1.282(10) N(1)eRueP(2) 85.60(18) N(3)eRueP(2) 104.37(18)
O(2)eC(22) 1.211(11) N(2)eRueP(2) 92.64(19) P(2)eRueP(1) 99.25(9)
Table 2
31P{1H} NMR and electrochemical data for complexes SCAR01-4.
Complex d (ppm) E1/2/Va ΔEp/Vb pKa (N-N)
SCAR01 PA (37.8)/PB (39.5) 1.21 0.21 4.44
SCAR02 PA (37.2)/PB (39.1) 1.14 0.17 4.92
SCAR03 PA (36.8)/PB (38.5) 1.32 0.19 2.61
SCAR04 PA (38.0)/PB (40.2) 1.22 0.13 4.27
a Scan rate: 100 mV s1.
b DEp ¼ EpaEpc.
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which is the best compound in this library [27]. On the other hand,
the compound SCAR06 showed low intracellular activity at 1.29 mM
(19.40%), compared to the similar compound SCAR01, with 55.10%
inhibition at a concentration of 0.95 mM (Table 4). This ﬁnding
corroborates the previous observation about the importance of the
presence of Hpic in the complex structure, to intensify the anti-
tuberculosis activity.
2.7. In vitro structureeactivityerelationship (SAR)
Indeed, although Hpic is the ligand with the lowest activity
among the tested ligands against MTB, its presence in the ruthe-
nium complexes increased both extra and intracellular activities.
For example, the substitution of the two Cl atoms by Hpic in the
cis-[RuCl2(dppb)(bipy)] (SCAR06), resulting in [Ru(pic)(dppb)(-
bipy)]PF6 (SCAR01), increased the anti-TB activity ﬁve times.
Therefore, it is likely that the structures of the complexes are
responsible for the properties of the compounds, and important
for their mechanism of action as tuberculostatics. The structural
changes probably affect the reaction of the complexes with
bacterial DNA, which is the likely target of these drugs. It is known
that the interaction with DNA is the basis of the cytostatic effect of
ruthenium compounds [30e32] and this interaction is modulated
by the nature of the ligands present in the complexes. In the
present case, the smaller partial electronic charge on the free
oxygen atom of the pic ligand, in comparison with the charges on
the chlorine atoms of the original compound [33], makes the
former the worst hydrogen bond acceptor. This could be associated
with a higher cytotoxicity [32] and probably the anti-MTB effect
follows the same trend.
In order to preliminary address if interaction with DNA could be
part of the mode of action of the complexes, experiments with CT
DNA were carried out. Binding of SCAR01 to DNA was studied by
combining atomic absorption determinations (for the metal) and
electronic absorption measurements for DNA quantiﬁcation. The
complex showed a negligible covalent binding level to CT DNA
(nmol Ru/mg DNA base pairs y 0). Interaction with DNA was
further explored through circular dichroism technique, viscosity
measurements and atomic force microscopy (AFM). In Fig. 2, the
circular dichroism spectra of SCAR01 at several ruthenium
complex: DNA molar ratios are shown. After 24 h of incubation at
37 C, changes in molar ellipticity can be observed for the complex.
Table 3
Anti-MTB activity (MIC), cytotoxicity (IC50), and selectivity index (SI) of the ruthenium complexes and their free ligands.
Identiﬁcation Compounds MIC IC50 SI
mg/mL mM mg/mL mM IC50/MIC
SCAR01 [Ru(pic)(dppb)(bipy)]PF6 0.91 0.95 31.30 32.60 34.20
SCAR02 [Ru(pic)(dppb)(Me-bipy)]PF6 0.49 0.50 11.70 11.90 23.90
SCAR03 [Ru(pic)(dppb)(Cl-bipy)]PF6 0.78 0.76 31.30 30.40 40.10
SCAR04 [Ru(pic)(dppb)(phen)]PF6 0.63 0.74 19.50 23 31.20
SCAR05 cis-[Ru(pic)(dppe)2]PF6 0.26a 0.22a 3.90 3.35 15.20
SCAR06 cis-[RuCl2(dppb)(bipy)] 3.90a 5.17a 78.20 104 20.10
Ligand Hpic > 50a >406a 312.50 2538  6.25
Ligand dppb > 50a >117.20a 625 1465  12.50
Ligand dppe 6.25a 15.70a 156.30 392.6 25
Ligand phen 2.34 11.80  9.80  50  4.20
Ligand bipy 25a 160.10a  9.80  63  0.40
Ligand Me-bipy 25a 135.70a  9.80  53.20  0.40
Ligand Cl-bipy 25 111.06 19.50 86.63 0.78
a Data reported previously [9,14].
Table 4
Intracellular activity against MTB Erdmann ATCC 35801 with pSMT1 plasmid, of ruthenium compounds and rifampin at various concentrations.
Identiﬁcation Compounds Concentrations Range Intracellular inhibitory
activities (%)
mg/mL mM
SCAR01 [Ru(pic)(dppb)(bipy)]PF6 3.64 3.80 77.50
0.91 0.95 55.10
0.23 0.24 48.30
SCAR02 [Ru(pic)(dppb)(Me-bipy)]PF6 1.96 2 82.30
0.49 0.50 73.30
0.12 0.13 70.50
SCAR03 [Ru(pic)(dppb)(Cl-bipy)]PF6 3.12 3.04 62.30
0.78 0.76 43.30
0.20 0.19 31.90
SCAR04 [Ru(pic)(dppb)(phen)]PF6 2.52 2.96 78.90
0.63 0.74 75.30
0.16 0.19 65.90
SCAR05 cis-[Ru(pic)(dppe)2]PF6 1.04 0.88 85.20
0.26 0.22 80.50
0.07 0.06 47.60
SCAR06 cis-[RuCl2(dppb)(bipy)] 15.6 20.70 51.10
3.90 5.17 33.40
0.98 1.29 19.40
RMP Rifampin 0.40 0.49 80.40
0.10 0.12 51.50
0.03 0.04 24
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These changes in the wavelength and the ellipticity of free DNA
indicate modiﬁcations in the secondary structure of DNA as
a consequence of its interaction with the complexes. Although the
substitution of ligands by N atoms of DNA bases could be
responsible, the most probable hypothesis is that weak interac-
tions occur between the ligands and DNA, through hydrogen
bonds.
The comparison of the AFM images of pBR322 DNA incubated
with SCAR01 (Fig. 3a) and of the free plasmid (Fig. 3b), show typical
modiﬁcations in the form of the DNA, namely super coiling, kinks
and compaction. These modiﬁcations indicate that SCAR01 inter-
acts with DNA. Additionally, the variation of viscosity with time at
25 C shows a decrease in the viscosity, which implies that there is
no intercalation of the complex between base pairs of the DNA. All
these results are in agreement with the structure of SCAR01 that
seems not to allow neither covalent binding to DNA bases nor
intercalation between bases.
It is known from the literature, that the KP1019 compound,
a tumour-inhibiting drug with a new mode of action, which
probably involves accumulation in transferrin receptor-(over)
expressing tumour cells via transferrin receptor, subsequent
reduction to RuII species, reacts with DNA and induction of
apoptosis via intrinsic mitochondrial pathway [34]. Bratsos et al.,
presented some ruthenium complexes containing 1-(2-Picolyl)-
substituted 1,2,3-triazole ligands showing their anticancer prop-
erties probably involving hydrolysis of the chloride ligand and
subsequent reaction with DNA [35]. Furthermore, another recent
study showed the cellular uptake and subcellular distribution
including adduct formation with genomic DNA and uptake into
mitochondria of two ruthenium(III)-based drugs in clinical trials,
KP1019 and NAMI-A, indicating that these ruthenium drugs have
distinct differences with respect to cisplatin, especially cisplatin-
resistant cells. In comparison to the sensitive cells, KP1019
exhibits higher cytotoxicity and a slightly changed metabolism of
the drug, whereas NAMI-A treatment results in increased intra-
cellular ruthenium levels and a higher number of ruthenium-DNA
adducts [36]. These data show that in fact the DNA can be a target
for ruthenium complexes but interaction with proteins cannot be
discarded as possible targets for ruthenium and other metal ions
complexes.
The structures of the complexes studied in this work are quite
different to the compounds containing chloride in their coordina-
tion sphere, what cause different interactions with the DNA. In this
case only the complex SCAR06 presents chloride coordinated to the
ruthenium, but it was showed that only one trans to the phos-
phorus atom is dissociated from the metal [37,38].
In a previous study we reported that for the complexes
[RuIIICl4(DMSO)(H-Hypoxanthine)] and [RuIIICl4(DMSO)[H-(N6-
butyladenine)] was possible to observe in the AFM images
a strong aggregation in plasmidic DNA forms [39]. No nuclease
activity was observed in any of these tested complexes and the
modiﬁcations observed conﬁrm that these complexes do not
destroy the structure of the pBR322 plasmid DNA but they yield
more coiled and/or more associated plasmids. As in that case, in our
present work we can observe aggregation of the forms but in
a lower degree; the complex does not destroy the structure of the
pBR322 plasmid DNA, no nuclease activity is observed. The com-
pacting of the forms, the supercoiled observed, are in good agree-
ment with the modiﬁcation observed in CD spectrum and viscosity
Fig. 2. Circular Dichroism spectra of plasmid rBR322 DNA and plasmid rBR322 DNA
incubated with the [Ru(pic)(dppb)(bipy)]PF6 (SCAR01) complex for 24 h, at 37 C at
molar ratios 0.1, 0.3 and 0.5.
Fig. 3. (a) AFM image of the plasmid rBR322 DNA incubated with the [Ru(pic)(dppb)(bipy)]PF6 (SCAR01) complex for 24 h, at 37 C. (b) AFM image of the free rBR322 DNA.
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measurements, which indicate interaction of the compound with
DNA, probably by electrostatic forces.
3. Conclusions
The synthesis and characterization of four new ruthenium
complexes has been described in this work. Additionally, biological
studies of these four ruthenium complexes and two other ones
together with those of the free ligands were presented. The results
reported here conﬁrm the biological activity of these ruthenium
complexes and raise the possibility of these compounds becoming
new drugs against TB.
4. Experimental section
4.1. Materials for synthesis
Solvents were puriﬁed by standard methods. All chemicals used
were of reagent grade or comparable purity. RuCl3∙3H2O, the
ligands 1,4-bis(diphenylphosphino)butane (dppb), 2,20-bipyridine
(bipy), 4,40-dimethyl-2,20-bipyridine (Me-bipy), 4,40-dichloro-2,20-
bipyridine (Cl-bipy), 1-10-phenanthroline (phen) and 2-
pyridinecarboxylic acid (Hpic) were used as received from
Aldrich. The complexes cis-[RuCl2(dppb)(N-N)], N-N ¼ bipy, Me-
bipy, Cl-bipy or phen were prepared according to published
procedures [15,22].
4.2. Instrumentation
The infrared spectrawere collected from CsI pellets in a Bomem-
Michelson 102 FTIR spectrometer, in the 4000e200 cm1 region.
UVevisible (UVeVis) spectra were recorded in a HP8452A (diode
array) spectrophotometer. All NMR experiments were performed at
293 K in a Bruker spectrometer, 9.4 T, observing 1H at 400.13, 13C at
100.61 and 31P{1H} at 161.98 MHz. The NMR spectra were recorded
in CDCl3, with TMS (1H and 13C) and 85% H3PO4 (31P{1H}) as internal
and external references, respectively. The splitting of proton,
carbon and phosphorus resonances, respectively, in the reported
1H, 13C and 31P{1H} NMR spectra, are deﬁned as d ¼ doublet. Mass
spectra were obtained in a QuattroLC Mass Spectrometer (Micro-
mass, triple-quadrupole, ESI/APCI, UK) equipped with syringe
pump (Phenix 40 pump, CE Instruments, Italy). The mobile phase
used to deliver the sample into the ion source by direct infusionwas
dichloromethane (HPLC grade, JT Baker, Mexico) with 0.1% formic
acid (v/v) (JT Baker, Mexico), ﬂowing at 100 mL/min. All analyses
were performed with an Electrospray Ionization (ESI) probe in the
positive ion mode. In each analysis, 10 mL of a standard solution
were injected at a concentration of 1 mg/mL. Cyclic voltammetry
experiments were carried out at room temperature in CH2Cl2
containing 0.10 M Bu4NClO4 (TBAP) (Fluka Purum), with a Bio-
analytical Systems Inc. BAS-100B/W electrochemical analyzer. The
working and auxiliary electrodes were stationary Pt foils; a Luggin
capillary probe was used and the reference electrode was Ag/AgCl.
Under these conditions, ferrocene is oxidized at 0.43 V (Fcþ/Fc). C, H
and N contents were determined in the Microanalytical Laboratory
of Universidade Federal de São Carlos, São Carlos (SP), with an EA
1108 Fisions Instruments CHNS microanalyser.
Complexes were tested for their DNA interaction ability using
native calf thymus DNA (CT DNA) (Type I) by a modiﬁcation of
a previously reported procedure [40,41]. CT DNA (50 mg) was dis-
solved in water (30 mL) (overnight). Solutions of the complexes in
DMSO (spectroscopy grade) (1 mL, 103 M) were incubated at 37 C
with solution of CT DNA (1 mL) during 96 h. DNA/complexes
mixtures were exhaustively washed to eliminate the un-reacted
complex. Quantiﬁcation of bound metal was done by atomic
absorption spectroscopy on a Perkin Elmer 5000 spectrometer.
Standards were prepared by diluting a metal standard solution for
atomic absorption spectroscopy. Final DNA concentration per
nucleotide was determined by UV absorption spectroscopy using
molar absorption coefﬁcient of 6000 M1 cm1 at 260 nm. The
reported values are mean of three determinations. For the circular
dichroismmeasurements, the SCAR01 complex was dissolved in an
aqueous solution (prepared with Milli-Q water) of 4% DMSO (2 mg
compound/5 mL). The stock solutions were freshly prepared before
use. The samples were prepared by the addition of aliquots of these
stock solutions to the appropriate volume of CT DNA in a TE buffer
solution (50 mM NaCl, 10 mM tris-(hydroxymethyl)aminomethane
hydrochloride (TriseHCl), 0.1 mM H4edta, pH 7.4) (5 mL). The
amount of complex added to the DNA solutionwas expressed as the
input molar ratio of Ru to nucleotide, calculated by formula (1)
ri ¼ m.Mnucl.Am/C.Mr.V (1)
where m ¼ mass of the compound (g); Mnucl ¼ mean nuclear
mass per nucleotide (330 g/mol); Am¼ number of themetal atoms;
C ¼ concentration of DNA (g/mL); Mr ¼ molar mass of the
compound (g/mol); V ¼ total volume of the sample (5 mL). A
solution of free native DNA in TE was used as a blank. The CD
spectra of DNA, in the presence and absence of complex (DNA
concentration 20 mg/mL, molar ratios ri ¼ 0.10, 0.30, 0.50), were
recorded at room temperature, after 24 h incubation at 37 C, on
a JASCO J-720 spectropolarimeter with a 450 W xenon lamp;
a computer was used for spectral subtraction and noise reduction.
Spectra for each sample were scanned twice, from 220 to 330 nm.
The plotted CD spectra are the average of three independent scans.
The data are expressed as average residue molecular ellipticity (q)
in degrees cm2 dmol1. Viscosity experiments were carried out in
an AND-SV-1 viscometer in a water bath with a water jacket, to
maintain the temperature at 25 C. A range of 200e370 mL of 5 mM
solutions of the compound were added to 2 mL of 100 mM CT DNA
Table 5
Crystallographic data and reﬁnement details for [Ru(pic)(dppb)(bipy)]PF6$2H2O
(SCAR01).
Empirical formula C44H40N3O2P2RuPF6$2H2O
Formula weight 986.80
Temperature (K) 293(2)
Crystal system Triclinic
Space group P-1
Unit cell dimensions
a (Å) 9.8971(6)
b (Å) 10.4187(5)
c (Å) 21.9290(10)
a (o) 99.985(3)
b (o) 100.073(4)
g (o) 95.853(3)
Volume (Å3) 2172.12(19)
Z 2
Density (calculated) (g cm3) 1.509
Absorption coefﬁcient (mm1) 0.543
F(000) 1008
Crystal size (mm3) 0.27  0.25  0.20
q range for data collection (o) 3.00e25.51
Limiting indices 11  h  11
12  k  12
26  l  26
Reﬂections collected 11900
Independent reﬂections (Rint) 7468 (0.0830)
Data/restraints/parameters 7468/0/560
Goodness-of-ﬁt on F2 1.004
Final R indices [I > 2s(I)] R1 ¼ 0.0729, wR2 ¼ 0.1739
R indices (all data) R1 ¼ 0.1208, wR2 ¼ 0.2359
Peak and hole/e Å3 1.298 and 1.807
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solution. The ﬂow time was measured by a digital stop watch. For
the Atomic Force Microscopy (TMAFM) experiment, plasmid
pBR322 DNA was heated at 60 C for 10 min to obtain the Open
Circular form (OC form). Stock solution was 1 mg/mL in a buffer
solution of HEPES (4 mM Hepes, pH 7.4/2 mMMgCl2). Each sample
contained 1 mL of pBR322 DNA at a concentration of 0.25 mg/mL, for
a ﬁnal volume of 40 mL. The amount of compound added is also
expressed as ri. AFM samples were prepared by placing a 3 mL drop
of test solution onto freshly cleaved Muscovite green mica disks as
the support. The drop was allowed to stand undisturbed for 3 min
to favour the adsorbateesubstrate interaction. Each DNA-laden disk
was rinsed with Milli-Q water and blown dry with clean
compressed argon gas directed normal to the disk surface. Samples
were stored over silica gel prior to AFM imaging. All AFM obser-
vations were made with a Nanoscope III Multimode AFM (Digital
Instruments, Santa Barbara, CA). Nano-crystal Si cantilevers of
length 125 nm, with an average spring constant of 50 N/m, termi-
nated with conical-shaped Si probe tips of apical radius 10 nm and
cone angle 35 were utilized. High-resolution topographic AFM
images were recorded in intermittent contact mode, at 1e3 Hz, in
air at room temperature (relative humidity <40%), on various
specimen areas of 2  2 mm.
4.3. X-ray crystallography
Orange [Ru(pic)(dppb)(bipy)]PF6$2H2O (SCAR 01) crystals were
grown by slow evaporation of a dichloromethane/n-hexane solu-
tion. The crystal was mounted on an Enraf-Nonius Kappa-CCD
diffractometer with graphite-monochromated Mo-Ka
(l ¼ 0.71073 Å) radiation. The ﬁnal unitecell parameters were
based on all reﬂections. Data collections were made with the
COLLECT program [42]; integration and scaling of the reﬂections
were performed with the HKL DENZO-SCALEPACK system of
programs [43]. A semi-empirical (from equivalents) absorption
correction was applied [43]. The structure was solved by direct
methods with SHELXS-97 [44]. The model was reﬁned by full-
matrix least squares on F2 by means of SHELXL-97 [45]. All
hydrogen atoms were stereochemically positioned and reﬁned
with a riding model. The ORTEP view of SCAR 01 is shown in Fig. 1
and was prepared with ORTEP-3 for Windows [46]. Hydrogen
atoms on the aromatic rings were reﬁned isotropically, each with
a thermal parameter 20% greater than the equivalent isotropic
displacement parameter of the atom towhich it is bonded. The data
collections and experimental details are summarized in Table 5. The
determined bond lengths and angles are not sufﬁciently accurate
for meaningful discussion; however, useful informationmay still be
gleaned from the diffraction study with respect the coordination
sphere of the metal.
4.4. Synthesis
The [Ru(pic)(dppb)(N-N)]PF6 complexes (N-N ¼ bipy, Me-bipy,
Cl-bipy or phen) were prepared by allowing 50 mg (ca. 0.07 mmol)
of the corresponding precursor cis-[RuCl2(dppb)(N-N)] dissolved in
25 mL of methanol to react with excess 2-pyridinecarboxylic acid
ligand (0.20 mmol;y24.6 mg) and 0.10 mmol (16.2 mg) of NH4PF6
under Ar atmosphere for 24 h. The ﬁnal red solutions were concen-
trated to ca. 3mL andwaterwas added to precipitate an orange solid,
whichwasﬁlteredoff,washedwellwithwater (35mL) anddiethyl
ether (3  5 mL) and dried in vacuo.
4.5. [Ru(pic)(dppb)(bipy)]PF6 (SCAR01) yield
47 mg (75%). Anal. Calcd for C44H40F6N3O2P3Ru: exptl (calc) C,
55.12 (55.58); H, 4.74 (4.24); N, 4.46 (4.42). 31P{1H} NMR: d(ppm)
39.5 (d); 37.8 (d), 2JP-P ¼ 33.5 Hz. UVeVis (CH2Cl2, 105 M): l/nm
(ε/M1 cm1) 259sh (2.20  104), 290 (2.58  104), 301sh
(2.22  104), 350sh (6.40  103), 422 (3.90  103), 490sh
(1.60  103). ESI (m/zþ): 806 [C44H40N3O2P2Ru]þ.
4.6. [Ru(pic)(dppb)(Me-bipy)]PF6 (SCAR02) yield
54 mg (70%). Anal. Calcd for C46H44F6N3O2P3Ru: exptl (calc) C,
56.25 (56.44); H, 4.50 (4.53); N, 4.23 (4.29). 31P{1H} NMR: d(ppm)
39.1 (d); 37.2 (d), 2JP-P ¼ 33.5 Hz. UVeVis (CH2Cl2, 105 M): l/nm
(ε/M1 cm1) 260sh (1.87  104), 288 (2.20  104), 300sh
(1.88  104), 352sh (5.90  103), 416 (3.90  103), 480sh
(1.30  103). ESI (m/zþ): 834 [C46H44N3O2P2Ru]þ.
4.7. [Ru(pic)(dppb)(Cl-bipy)]PF6 (SCAR03) yield
61mg (80%). Anal. Calcd for C44H38F6N3O2P3RuCl2: exptl (calc) C,
51.73 (51.83); H, 4.17 (3.76); N, 4.21 (4.12). 31P{1H} NMR: d(ppm)
38.5 (d); 36.8 (d), 2JP-P ¼ 33.5 Hz. UVeVis (CH2Cl2, 105 M): l/nm
(ε/M1 cm1) 259sh (2.33  104), 294 (2.36  104), 337sh
(9.60  103), 453 (4.50  103), 515sh (1.70  103). ESI (m/zþ): 874
[C44H38N3O2P2RuCl2]þ.
4.8. [Ru(pic)(dppb)(phen)]PF6 (SCAR04) yield
56 mg (74%). Anal. Calcd for C46H40F6N3O2P3Ru: exptl (calc) C,
57.00 (56.68); H, 4.57 (4.14); N, 4.56 (4.31). 31P{1H} NMR: d(ppm)
40.2 (d); 38.0 (d), 2JP-P ¼ 33.6 Hz. UVeVis (CH2Cl2, 105 M): l/nm
(ε/M1 cm1) 234 (6.99  104), 290 (2.91  104), 300 (2.88  104),
408 (4.06  103). ESI (m/zþ): 830 [C46H40N3O2P2Ru]þ.
4.9. Anti-M. tuberculosis activity assay
The anti-MTB activity of the compounds was determined by the
Resazurin Microtiter Assay (REMA) [47]. Stock solutions of the test
compounds were prepared in dimethyl sulfoxide (DMSO) and
diluted in Middlebrook 7H9 broth (Difco), supplemented with oleic
acid, albumin, dextrose and catalase (OADC enrichment - BBL/
Becton Dickinson, Sparks, MD, USA), to obtain ﬁnal drug concen-
tration ranges from 0.15 to 250 mg/mL. The serial dilutions were
realized in a Precision XS Microplate Sample Processor (Biotek).
The isoniazid was dissolved in distilled water, as recommended by
the manufacturer (Difco laboratories, Detroit, MI, USA), and used as
a standard drug. MTB H37Rv ATCC 27294 was grown for 7e10 days
in Middlebrook 7H9 broth supplemented with OADC, plus 0.05%
Tween 80 to avoid clumps. Cultures were centrifuged for 15 min at
3150 g, washed twice, and resuspended in phosphate-buffered
saline and aliquots were frozen at 80 C. After 2 days, an aliquot
was thawed to determine the viability and the Colony-Forming Unit
(CFU) after freezing. MTB H37Rv (ATCC 27294) was thawed and
added to the test compounds, yielding a ﬁnal testing volume of
200 mL with 2  104 CFU/mL. Microplates with serial dilutions of
each compound were incubated for 7 days at 37 C, after resazurin
was added to test viability. Wells that turned from blue to pink,
with the development of ﬂuorescence, indicated growth of bacte-
rial cells, while maintenance of the blue colour indicated bacterial
inhibition [25,47]. The ﬂuorescence was read (530 nm excitation
ﬁlter and 590 nm emission ﬁlter) in a SPECTRAﬂuor Plus (Tecan)
microﬂuorimeter. The MIC was deﬁned as the lowest concentration
resulting in 90% inhibition of growth of MTB [25]. As a standard
test, the MIC of isoniazid was determined on each microplate. The
acceptable range of isoniazid MIC is from 0.015 to 0.06 mg/mL
[25,47]. Each test was set up in triplicate.
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4.10. Cytotoxicity assay
In vitro cytotoxicity assays (IC50) were performed on the J774A.1
(ATCC TIB-67) mouse cell line, as recommended by Pavan et al. [3]
The cells were routinely maintained in complete medium (RPMI-
1640 supplemented with 10% heat-inactivated fetal bovine serum
(FBS) plus 100 U/mL penicillin and 100 mg/mL streptomycin), at
37 C, in a humidiﬁed 5% CO2 atmosphere. After reaching conﬂu-
ence, the cells were detached and counted. For the cytotoxicity
assay, 1 105 cells/mL were seeded in 200 mL of complete medium
in 96-well plates (NUNC). The plates were incubated at 37 C
under a 5% CO2 atmosphere for 24 h, to allow cell adhesion prior to
drug testing. The compounds were dissolved in DMSO (5%) and
subjected to two-fold serial dilution from 1250 to 3.9 mg/mL. Cells
were exposed to the compounds at various concentrations for 24 h.
Resazurin solution was then added to the cell cultures and incu-
bated for 6 h. Cell respiration, as an indicator of cell viability, was
detected by reduction of resazurin to resoruﬁn, whose pink colour
and ﬂuorescence indicates cell viability. A persistent blue colour of
resazurin is a sign of cell death [25,47]. The ﬂuorescence
measurements (530 nm excitation ﬁlter and 590 nm emission
ﬁlter) were performed in a SPECTRAﬂuor Plus (Tecan) micro-
ﬂuorimeter. The IC50 value was deﬁned as the highest drug
concentration at which 50% of the cells are viable relative to the
control [3]. Each test was set up in triplicate.
4.11. Selectivity index
The selectivity index (SI) was calculated by dividing IC50 for the
mouse cells by the MIC for the pathogen; if the SI is 10, the
compound is then investigated further [29].
4.12. In vitro infection model
The intracellular anti-MTB activity of the compounds was
determined by in vitro infection model, as suggested by Snewin
et al. [48] MTB Erdmann (ATCC 35801) containing the Luciferase
Plasmid (pSMT1) [49] was cultured in Middlebrook 7H9 broth
supplemented with OADC and hygromycin (50 mg/mL). The
suspensionwas then seeded onMiddlebrook 7H10 (solid medium),
supplemented with OADC, for CFU/mL counts. The luminescence
(RLU - Relative Luminescence Units) of the suspension was read in
a SPECTRAﬂuor Plus (TECAN), after adding the substrates, namely,
0.1 ml of 1% n-decyl aldehyde (Sigma) in ethanol [50], and
compared with the CFU/mL. The comparison between RLU/mL and
CFU/mL was carried out three times (at 0, 3 and 7 days) (Fig. 4). The
J774A.1 (ATCC TIB-67) murine macrophage-like cell line was
routinely maintained in RPMI-1640 complete medium (see cyto-
toxicity assay), at 37 C and 5% CO2. After reaching conﬂuence, the
cells were detached and counted. For the intracellular anti-MTB
activity, 5 x 105 cells/mL were seeded in a 24-well plate (NUNC)
(1 mL per well) at 37 C and 5% CO2, for 24 h. The plates were
incubated at 37 C under a 5% CO2 atmosphere for 24 h to allow cell
adhesion prior to drug testing. Bacterial suspensions were washed
three times in phosphate-buffered saline (PBS) by centrifuging at
2200 g for 10 min and resuspended in RPMI-1640 complete
medium. Cells were infected by incubation with 1e5 bacteria per
cell for 1 h at 37 C and then washed three times with Hanks
balanced salt solution (GIBCO BRL). The total number of cell-
associated mycobacteria was initially determined, as follows.
J774A.1 cells were lysed by the addition of 1 mL of sterile distilled
water containing 0.1% Triton X-100 per well. The bacteria that were
internalized in macrophages showed luminescence, conﬁrming the
infection. The complexes were diluted in RPMI-1640 complete
medium at the following concentrations: MIC value, 4 times higher
and 4 times lower than MIC (1 mL per well at each concentration).
Our previous studies showed that incubation for 3 days is an
optimal period. Thus, the plates were incubated for 3 days at 37 C
and 5% CO2 and then washed and lysed. The RLU was determined
and the percent inhibition by each compound at each concentration
was calculated, based on the positive control test. As a standard
test, the intracellular inhibition by rifampin was determined
(Table 4). Each test was set up in triplicate.
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Appendix. Supplementary Material
Crystallographic data for the structural analysis for the complex
[Ru(pic)(dppb)(bipy)]PF6$2H2O (SCAR 01) discussed here have
been deposited at the Cambridge Crystallographic Data Centre, 12
Union Road, Cambridge, CB2 1EZ, UK and is available on request
quoting the deposition number CCDC 817301. These supplementary
data can be obtained free of charge via http://www.ccdc.cam.ac.uk/
conts/retrieving.html.
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